News
If you have a media-related inquiry, please contact William Janzen.
Recent News
January 25, 2012 - Chaperone Therapeutics receives second award from The Michael J. Fox Foundation to develop therapies for Parkinson's disease.
December 1, 2011 - Dennis J. Thiele, Ph.D., a Founder of Chaperone Therapeutics and George Barth Geller Professor of Pharmacology and Cancer Biology at Duke University Medical Center, has published a review titled "HSF1 as a therapeutic target in neurodegenerative disease" in Nature Reviews Drug Discovery. The article is featured as the cover illustration.
June 3, 2010 - Chaperone receives a Small Business Research Loan from North Carolina Biotechnology Center to advance the therapeutics into animals.
March 3, 2010 - Dennis J. Thiele, Ph.D., a Founder of Chaperone Therapeutics and George Barth Geller Professor in Pharmacology and Cancer Biology at Duke University Medical Center, receives the 2010 Health Care innovation award from the Triangle Business Journal for his work on the treatment of protein folding diseases.
January 20, 2010 - Compounds that help protect nerve cells discovered by duke team. For more information, see Lev Osherovich, "Turning up the heat on HD" (SciBX. 2010 February 8; 3(7)) and Neef DW, Turski ML, Thiele DJ, "Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease" (PLoS Biol. 2010 January; 8(1):e1000291).
November 30, 2009 - Chaperone Therapeutics receives award from The Michael J. Fox Foundation to develop therapies for Parkinson's disease.
October 30, 2009 - Chaperone Therapeutics licenses key Technology from Duke Medical Center.